Rational use of sublingual opioids in palliative medicine

Journal of Palliative Medicine

Volumn 10, Issue 2, 2007, Pages 465-475

  Reisfield, Gary M ^a   Wilson, George R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; OPIATE; OXYCODONE; SUFENTANIL;

ADVANCED CANCER; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; KIDNEY FAILURE; NEUROPATHIC PAIN; PALLIATIVE THERAPY; RESPIRATION DEPRESSION; REVIEW;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; HOSPICE CARE; HUMANS; PAIN, INTRACTABLE; PALLIATIVE CARE; TERMINALLY ILL;

EID: 34248329090     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.0150     Document Type: Review

References (88)

1. Pannuti F, Rossi AP, Iafelice G, Marraro D, Camera P, Cricca A, Strocchi E, Burroni P, Lapucci L, Fruet F.l: Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal and sublingual route. Clinical report and preliminary results on morphine pharmacokinetics. Pharmacol Res Commun 1982;14:369-380.
2. Pitorak EF, Kraus JC: Pain control with sublingual morphine. The advantages for hospice care. Am J Hosp Care 1987;4:39-41.
3. Enck RE: Mucosal membranes as alternative routes for morphine sulfate administration. Am J Hosp Care 1988;5:17-18.
4. Zeppetella G: Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001;15:323-328.
5. Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, Nash D, Pappagallo M, Payne R, Ray J, Viscusi E, Wong W: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management. Pharmacy and Therapeutics 2005;30:354-361.
6. DeBoer AG, De Leede LGJ, Breimer DD: Drug absorption by sublingual and rectal routes. Br J Anaesth 1984;56:69-82.
7. Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S, Houde RW, Foley KM: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-343.
8. Osborne R, Joel S, Trew D, Slevin M: Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990;47:12-19.
9. Robison JM, Wilkie DJ, Campbell B: Sublingual and oral morphine administration. Nurs Clin North Am 1995;30:725-743.
10. McQuay HJ, Moore RA, Bullingham RES: Subligual morphine, heroin, methadone, and buprenorphine: kinetics and effects. In: Foley KM, Inturrisi CE (eds): Advances in Pain Research and Therapy. New York: Raven Press, 1986, pp. 407-412.
11. Harris D, Robinson JR: Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992;81:1-10.
12. Shojaei AH: Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Pharmaceut Sci 1998;1:15-30.
13. Aframian DJ, Davidowitz T, Benoliel R: The distribution of oral mucosal pH values in healthy saliva secretors. Oral Diseases 2006;12:420-423.
14. Whitman HH: Sublingual morphine: A novel route of narcotic administration. Am J Nursing 1984;84:939-940.
15. Hirsh JD: Sublingual morphine sulfate in chronic pain management. Clin Pharm 1984;3:585.
16. Tassinari D, Masi A, Sartori S, Nielsen I, Ravaioli A: Atypical absorption of morphine sulfate through oral mucosa: An unusual case of acute opioid poisoning. J Pain Symptom Manage 1995;10:405-407.
17. Coluzzi PH: Sublingual morphine: efficacy reviewed. J Pain Symptom Manage 1998;16:184-192.
18. Davis T, Miser AW, Loprinzi CL, Kaur JS, Burnham NL, Dose AM, Ames MM: Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Hosp J 1993;9:85-90.
19. Watson NW, Taylor KMG, Joel SP, Slevin ML, Eden OB: A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. J Pharm Pharmacol 1996;48:1256-1259.
20. Engelhardt T, Crawford M: Sublingual morphine may be a suitable alternative for pain control in children in the postoperative period. Paediatric Anaesthesia 2001;11:81-83.
21. Kokki H, Rasanen I, Laisalmi M: Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. Clin Pharmacokinet 2006;45:745-754.
22. Al-Ghannaneem AM, Malkawi AH, Crooks PA: Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech 2006;7:E1-E5.
23. Fisher K, Stiles C, Hagen NA: Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage 2004;28:629-625.
24. Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatsas ML: Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Deliv 2006;13:269-276.
25. Aronoff GM, Brennan MJ, Pritchard DD, Ginsberg B. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005;6:305-314.
26. 〈www.archimedespharma.com/newseventsNews. html〉 (Last accessed September 9, 2006).
27. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005;44:1279-1286.
28. Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H: Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: A new approach to treatment of incident pain. Br J Clin Pharmacol 2004;59:249-253.
29. Gardner-Nix J: Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage 2001;22:627-629.
30. Stoelting RK: Opioid agonists and antagonists. In: Pharmacology and Physiology in Anesthetic Practice. Philadelphia: J.B. Lippincott, 1987, p. 86.
31. Kedlaya D, Reynolds L, Waldman S: Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 2002;16:651-665.
32. Helmers JH, Noorduin H, Van Peer A, Van Leeuwen L, Zuurmond WW: Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989;36:494-497.
33. Kunz KM, Theisen JA, Schroeder ME: Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage 1993;8:189-190.
34. Jackson K, Keech J: Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain [letter]. J Pain Symptom Manage 2002;23:450-452.
35. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504.
36. Tegeder I, Lotsch J, Geisslinger G: Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37:17-40.
37. Duncan A: The use of fentanyl and alfentanil sprays for episodic pain. Palliat Med 2002;16:550.
38. Lisney F: 〈www.berkshire.nhs.uk/tips/documents/ Presentations/2005/ SeptCancer/opioid%20analgesics%20for%20cancer%20pain%20in%20primary%20care%20- %20Dr%20Lisney.pdf〉 (Last accessed July 19, 2006).
39. Hall EJ, Sykes NP: Analgesia for patients with advanced disease: 1. Postgrad Med J 2004;80:148-154.
40. Schuh KJ, Walsh SL, Bigelow GE, Preston KL, Stitzer ML: Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 1996;278:836-846.
41. Robbie DS: A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmac 1979;7:315S-317S.
42. Lari S, Fabbri G, Mattioli R, Elmar K: Epidural buprenorphine versus morphine in bone cancer pain. Minerva Anestesiol 1985;51:609-614.
43. Pasqualucci V, Tantucci C, Paoletti F, Dottorini ML, Bifarini G, Belfiori R, Berioli MB, Grassi V, Sorbini CA: Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effect and analgesic activity. Pain 1987;29:273-286.
44. Hashimoto Y, Utsumi T, Tanioka H, Rigor BM: Epidural buprenorphine or morphine for the relief of head and neck cancer pain. Anesth Prog 1991;38:69-71.
45. Francaviglia N, Silvestro C, Carta F, Davini V, Perria C, Scaricabarozzi I, Cipolla PV: Subarachnoid buprenorphine administered by implantable micropumps. Acta Neurochir 1990;102:62-68.
46. Noda J, Umeda S, Arai T, Harima A, Mori K: Continuous subcutaneous infusion of buprenorphine for cancer pain control. Clin J Pain 1989;5:147-152.
47. Manzi R, Rizzi M, D'Elia F, Perego G, Scaricabarozzi I, Prada A, Terno G: Use of buprenorphine after right hepatectomy. Minerva Anesthesiol 1991;57:379-382.
48. Kjaer M, Henriksen H, Knudsen J: A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol 1982;13:487-492.
49. Taguchi T: Effect of a long-acting analgesic, burpenorphine on cancer pain - A single blind crossover comparison with pentazocine. Gan To Kagaku Ryoho 1982;9:250-257.
50. Bohme K: Buprenorphine in a transdermal therapeutic system - A new option. Clin Rheumatol 2002;21 (Suppl 1):S13-S16.
51. Sittl R, Griessinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-168.
52. Likar R, Griessinger N, Sadjak A, Sittl R: Transdermal buprenorphine for treatment of chronic tumor and nontumor pain. Wien Med Wochenschr 2003;153:317-322.
53. Radbruch L: Buprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Supple 2003;133:19-24.
54. Sorge J, Sittl R: Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1808-1820.
55. Muriel C, Failde I, Mico JA: Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective observational clinical study. Clin Ther 2005;27:451-462.
56. Griessinger N, Sittle R, Likar R: Transdermal buprenorphine in clinical practice - A post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147-1156.
57. Davis M: Buprenorphine in cancer pain. Support Care Cancer 2005;13:878-887.
58. Sittl R: Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006;20:s25-s30.
59. Johnson RE, Fudala PJ, Payne R: Buprenorphine: Considerations for pain management. J Pain Symptom Manage 2005;29:297-326.
60. Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD: Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996;20:369-378.
61. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-580.
62. Heel RC, Brogden RN, Speight TM, Avery GS: Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-110.
63. Lufty K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJl: Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid-like receptors. J Neurosci 2003;23:10331-10337.
64. Christoph T, Kogel B, Schiene, Meen M, DeVry J, Friderichs E: Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98.
65. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof N: Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-632.
66. Budd K, Collett BJ: Old dog - New (ma)trix. Br J Anaesth 2003;90:722-724.
67. Evans HC, Easthope SE: Transdermal buprenorphine. Drugs 2003;63):1999-2010.
68. Zenz M, Piepenbrock S, Tryba M, Glocke M, Everlien M, Klauke W: Long-term therapy of cancer pain. A controlled study on buprenorphine. Dtsch Med Wochenschr 1985;110:448-452.
69. Brema F, Pastorino G, Martini MC, Gottlieb A, Luzzani M, Libretti A, Sacca L, Cigolari S: Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 1996;16:109-116.
70. Bono AV, Cuffari S: Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine. Drugs 1997;53(Suppl 2):40-49.
71. Budd K: High dose buprenorphine for postoperative analgesia. Anaesthesia 1981;36:900-903.
72. Malinoff HL, Barkin RL, Wilson G: Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005;12:379-384.
73. Johnson RE, Strain EC, Amass L: Buprenorphine: How to use it right. Drug Alcohol Depend 2003;70:S59-S77.
74. Strain ED, Preston KL, Liebson IA, Bigelow GE: Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992;261:985-993.
75. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML: Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995;119:268-276.
76. Mendelson J, Jones RT, Welm S, Brown J, Batki SL: Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 1997;41:1095-1101.
77. Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001;154:230-242.
78. Shriek P: Treatment of cancer-related pain with transdermal buprenorphine: A report of three cases. Support Care Cancer 2004;12:882-884.
79. Walsh SL, Preston KL, Bigelow GE, Stitzer ML: Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-372.
80. Mercandante S, Villari P, Ferrara P, Porzio G, Aielli F, Verna L, Casuccio A: Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006;32:175-179.
81. Skaer TL: Practice guidelines for transdermal opioids in malignant pain. Drugs 2004;64:2629-2638.
82. Sittl R, Likar R, Poulsen Natrup B: Equipotent doses of transdermal fentanyl and buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther 2005;27:225-237.
83. Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, Schutler J: Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005;118:15-22.
84. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M: Comparison of the respiratory effects of intravenous buprenorphine, fentanyl in humans and rats. Br J Anaesth 2005;94:825-834.
85. Boger RH: Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006;20:S17-S23.
86. Wilkinson GR: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill, 2001, p. 3.
87. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March 1994.
88. Schuh KJ, Johanson CE: Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 1999;56:55-60.